CN102159239A - 针对hpv的疫苗 - Google Patents
针对hpv的疫苗 Download PDFInfo
- Publication number
- CN102159239A CN102159239A CN200980135875XA CN200980135875A CN102159239A CN 102159239 A CN102159239 A CN 102159239A CN 200980135875X A CN200980135875X A CN 200980135875XA CN 200980135875 A CN200980135875 A CN 200980135875A CN 102159239 A CN102159239 A CN 102159239A
- Authority
- CN
- China
- Prior art keywords
- hpv
- vaccine
- purposes
- dose
- doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 169
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 194
- 208000015181 infectious disease Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 16
- 239000002245 particle Substances 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 65
- 239000002671 adjuvant Substances 0.000 claims description 39
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 9
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 5
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 3
- 241000700605 Viruses Species 0.000 abstract description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 136
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
- 230000002163 immunogen Effects 0.000 description 35
- 238000002255 vaccination Methods 0.000 description 32
- 239000000427 antigen Substances 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 239000011780 sodium chloride Substances 0.000 description 18
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 18
- 239000000872 buffer Substances 0.000 description 15
- 230000005847 immunogenicity Effects 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000001914 filtration Methods 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 229960002566 papillomavirus vaccine Drugs 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 229940124957 Cervarix Drugs 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 9
- 238000000108 ultra-filtration Methods 0.000 description 9
- 238000005571 anion exchange chromatography Methods 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 7
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- -1 phosphoryl lipid Chemical class 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000005349 anion exchange Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- KEQFTVQCIQJIQW-UHFFFAOYSA-N N-Phenyl-2-naphthylamine Chemical compound C=1C=C2C=CC=CC2=CC=1NC1=CC=CC=C1 KEQFTVQCIQJIQW-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 241000255993 Trichoplusia ni Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 229940124897 Gardasil Drugs 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100001223 noncarcinogenic Toxicity 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- 101150061050 CIN1 gene Proteins 0.000 description 1
- 101150070189 CIN3 gene Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150075239 L1 gene Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001399 aluminium compounds Chemical class 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 101150005988 cin2 gene Proteins 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8510108P | 2008-07-31 | 2008-07-31 | |
| US61/085,101 | 2008-07-31 | ||
| US17656109P | 2009-05-08 | 2009-05-08 | |
| US61/176,561 | 2009-05-08 | ||
| PCT/EP2009/059820 WO2010012780A1 (en) | 2008-07-31 | 2009-07-29 | Vaccine against hpv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102159239A true CN102159239A (zh) | 2011-08-17 |
Family
ID=41139260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980135875XA Pending CN102159239A (zh) | 2008-07-31 | 2009-07-29 | 针对hpv的疫苗 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20110189229A1 (enExample) |
| EP (1) | EP2318042B1 (enExample) |
| JP (1) | JP6022159B2 (enExample) |
| KR (1) | KR20110053340A (enExample) |
| CN (1) | CN102159239A (enExample) |
| AU (1) | AU2009275909A1 (enExample) |
| BR (1) | BRPI0916732B1 (enExample) |
| CA (1) | CA2732436C (enExample) |
| CO (1) | CO6341567A2 (enExample) |
| DK (1) | DK2318042T3 (enExample) |
| DO (1) | DOP2011000031A (enExample) |
| EA (1) | EA201170264A1 (enExample) |
| ES (1) | ES2519490T3 (enExample) |
| HR (1) | HRP20141063T1 (enExample) |
| IL (1) | IL210977A0 (enExample) |
| MA (1) | MA32554B1 (enExample) |
| MX (1) | MX2011001218A (enExample) |
| NZ (1) | NZ590919A (enExample) |
| PE (1) | PE20110327A1 (enExample) |
| PL (1) | PL2318042T3 (enExample) |
| PT (1) | PT2318042E (enExample) |
| RS (1) | RS53607B1 (enExample) |
| SI (1) | SI2318042T1 (enExample) |
| SM (1) | SMT201400170B (enExample) |
| WO (1) | WO2010012780A1 (enExample) |
| ZA (1) | ZA201100889B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010264695A1 (en) | 2009-06-25 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease |
| CN102178944A (zh) * | 2010-09-17 | 2011-09-14 | 大连雅立峰生物制药有限公司 | 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用 |
| CN102229660B (zh) * | 2011-05-25 | 2015-04-22 | 厦门大学 | 截短的人乳头瘤病毒33型l1蛋白 |
| KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
| AU2015313756A1 (en) * | 2014-09-11 | 2017-03-09 | Cadila Healthcare Limited | Superior human papilloma virus antigens with superior immunological properties and vaccine containing it |
| US10063211B2 (en) | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| RU2628693C1 (ru) * | 2016-11-10 | 2017-08-21 | федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) | РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ |
| US20210302427A1 (en) * | 2020-03-31 | 2021-09-30 | Shuhari Group, LLC | Secure Immunity Information Transmission System And Network |
| WO2025147639A1 (en) * | 2024-01-04 | 2025-07-10 | Cyanvac Llc | Improved formulation providing increased stability for vaccines composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1618465A (zh) * | 1999-09-07 | 2005-05-25 | 史密丝克莱恩比彻姆生物有限公司 | 联合疫苗组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089164A2 (en) * | 2003-12-31 | 2005-09-29 | Pharmexa Inc. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| US7758866B2 (en) * | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| WO2005123125A1 (en) * | 2004-06-16 | 2005-12-29 | Glaxosmithkline Biologicals S.A. | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
| WO2006114312A2 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
-
2009
- 2009-07-29 JP JP2011520506A patent/JP6022159B2/ja active Active
- 2009-07-29 AU AU2009275909A patent/AU2009275909A1/en not_active Abandoned
- 2009-07-29 WO PCT/EP2009/059820 patent/WO2010012780A1/en not_active Ceased
- 2009-07-29 PL PL09781248T patent/PL2318042T3/pl unknown
- 2009-07-29 SI SI200931047T patent/SI2318042T1/sl unknown
- 2009-07-29 CA CA2732436A patent/CA2732436C/en active Active
- 2009-07-29 DK DK09781248.1T patent/DK2318042T3/da active
- 2009-07-29 US US13/056,452 patent/US20110189229A1/en not_active Abandoned
- 2009-07-29 KR KR1020117004436A patent/KR20110053340A/ko not_active Withdrawn
- 2009-07-29 MX MX2011001218A patent/MX2011001218A/es not_active Application Discontinuation
- 2009-07-29 EA EA201170264A patent/EA201170264A1/ru unknown
- 2009-07-29 PT PT97812481T patent/PT2318042E/pt unknown
- 2009-07-29 RS RS20140613A patent/RS53607B1/sr unknown
- 2009-07-29 PE PE2011000104A patent/PE20110327A1/es not_active Application Discontinuation
- 2009-07-29 NZ NZ590919A patent/NZ590919A/xx not_active IP Right Cessation
- 2009-07-29 HR HRP20141063AT patent/HRP20141063T1/hr unknown
- 2009-07-29 ES ES09781248.1T patent/ES2519490T3/es active Active
- 2009-07-29 EP EP09781248.1A patent/EP2318042B1/en active Active
- 2009-07-29 BR BRPI0916732-3A patent/BRPI0916732B1/pt active IP Right Grant
- 2009-07-29 CN CN200980135875XA patent/CN102159239A/zh active Pending
-
2011
- 2011-01-28 DO DO2011000031A patent/DOP2011000031A/es unknown
- 2011-01-31 IL IL210977A patent/IL210977A0/en unknown
- 2011-02-03 ZA ZA2011/00889A patent/ZA201100889B/en unknown
- 2011-02-11 MA MA33605A patent/MA32554B1/fr unknown
- 2011-02-23 CO CO11022213A patent/CO6341567A2/es not_active Application Discontinuation
-
2014
- 2014-11-10 SM SM201400170T patent/SMT201400170B/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1618465A (zh) * | 1999-09-07 | 2005-05-25 | 史密丝克莱恩比彻姆生物有限公司 | 联合疫苗组合物 |
Non-Patent Citations (1)
| Title |
|---|
| HERRERO R. ET AL: "Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.", 《VACCINE》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201100889B (en) | 2012-04-25 |
| DOP2011000031A (es) | 2011-02-28 |
| AU2009275909A1 (en) | 2010-02-04 |
| CA2732436A1 (en) | 2010-02-04 |
| PE20110327A1 (es) | 2011-06-29 |
| EP2318042A1 (en) | 2011-05-11 |
| PT2318042E (pt) | 2014-11-05 |
| WO2010012780A1 (en) | 2010-02-04 |
| HRP20141063T1 (hr) | 2015-01-02 |
| MX2011001218A (es) | 2011-03-15 |
| ES2519490T3 (es) | 2014-11-07 |
| IL210977A0 (en) | 2011-04-28 |
| CO6341567A2 (es) | 2011-11-21 |
| NZ590919A (en) | 2012-10-26 |
| MA32554B1 (fr) | 2011-08-01 |
| JP2011529475A (ja) | 2011-12-08 |
| BRPI0916732A2 (pt) | 2017-01-31 |
| SMT201400170B (it) | 2015-01-15 |
| RS53607B1 (sr) | 2015-04-30 |
| JP6022159B2 (ja) | 2016-11-09 |
| PL2318042T3 (pl) | 2015-02-27 |
| CA2732436C (en) | 2018-01-16 |
| KR20110053340A (ko) | 2011-05-20 |
| DK2318042T3 (da) | 2014-11-10 |
| EA201170264A1 (ru) | 2011-08-30 |
| SI2318042T1 (sl) | 2014-12-31 |
| EP2318042B1 (en) | 2014-08-20 |
| US20110189229A1 (en) | 2011-08-04 |
| BRPI0916732B1 (pt) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102159239A (zh) | 针对hpv的疫苗 | |
| CN103028113B (zh) | 疫苗 | |
| JP4546092B2 (ja) | ワクチン | |
| EP2044953A1 (en) | Viral antigens | |
| JP2023101815A (ja) | 髄膜炎菌（Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法 | |
| MX2011013744A (es) | Construcciones novedosas de proteinas del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv. | |
| CN113354740B (zh) | 一种猪瘟病毒自组装蛋白纳米颗粒、制备方法及应用 | |
| US20050287161A1 (en) | Vaccine | |
| WO2004052395A1 (en) | L2-peptide of the human papillomavirus associated with virus-like particles | |
| EP1758609B1 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
| KR101359943B1 (ko) | Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는 52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 | |
| KR20080005585A (ko) | 백신 | |
| US7758866B2 (en) | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 | |
| US20070020288A1 (en) | Vaccine | |
| CN101217975A (zh) | 疫苗 | |
| Mandić | Prophylactic HPV vaccines | |
| KR20080005583A (ko) | 백신 | |
| BRPI0610032A2 (pt) | uso de uma proteìna l1 do papilomavìrus humano ou fragmento imunogêico da mesma de um primeiro tipo de hpv, programa de vacinação para proteção contra a infecção e/ou doença por hiv, método para prevenção da infecção e/ou doença por hpv, composição de vacina, e, kit | |
| BRPI0610396A2 (pt) | vacina de hpv multivalente, métodos para proteger um paciente contra a infecção, para prevenir ou reduzir a freqüênca de anormalidades citológicas em um paciente, para prevenir a formação de lesões cin histologicamente confirmadas e para fabricar a vacina, e, usos de uma composição, de uma vacina e de uma composição de vacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110817 |